GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

VISEN Pharmaceuticals 2561.HK · HKD

N/A · HKEX · 🇭🇰 Hong Kong

Compare

12.40

-6.63%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About VISEN Pharmaceuticals

Its shares trade on HKEX under the ticker 2561.HK. It has been listed since 21 March 2025. In the fiscal year to 31 December 2025, it reported revenue of CN¥160,729 and a net loss of CN¥246.9m. At that date it held total assets of CN¥977.7m and shareholders' equity of CN¥762.4m.

VISEN Pharmaceuticals operates as a biopharmaceutical company. The company is headquartered in Suzhou, Anhui. The company went IPO on 2025-03-21. The firm is committed to providing endocrine disease products and treatment solutions, including adult endocrinology, pediatric endocrinology, and endocrine rare diseases. The firm's product pipelines include lonapegsomatropin, palopegteriparatide and others.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
21 Mar 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Suzhou, China
  • IPO scheduled for 2025-03-21
  • Focus on endocrine disease products and treatment solutions

Weaknesses

  • Sector and industry listed as N/A
  • Product pipeline details limited to three named products
  • Source description indicates untrusted facts

Opportunities

  • Growth potential in endocrine disease treatment markets
  • Expansion of product pipelines beyond current named products
  • Potential for international market entry

Threats

  • Untrusted source description may affect credibility
  • IPO date is in the future, creating uncertainty
  • Sector and industry classification as N/A may limit investor interest

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.